Pacira Biosciences, Inc. (PCRX)

Pacira Biosciences' stock price has been impacted by several events in the past six months. Preliminary Q4 revenues missed estimates, leading to a stock decline. An agreement with LG Chem was announced to expand EXPAREL availability. DOMA Perpetual Capital Management nominated director candidates. Pacira joined the PROBE Consortium. Results from a study on the iovera system were announced. DOMA Perpetual Capital Management urged Pacira's board to explore a sale of the company. Q3 2025 earnings were released, with EPS beating estimates but revenue falling short. Insider selling was reported. The share price increased by 35.49% between January 7, 2025, and January 6, 2026.

Historically, the first quarter represented a higher percentage of Pacira's full-year sales, but in 2023, the first three quarters became more evenly balanced. A seasonal chart analysis indicates a historical "Buy Date" of November 7 and a "Sell Date" of February 6. The company's educational programs and focus on expanding market access aim to drive consistent demand throughout the year.

Pacira Biosciences, Inc. is a specialty pharmaceutical company in the Healthcare sector, focusing on Biotechnology and Pharmaceuticals. Its mission is to advance pain relief science and provide non-opioid alternatives, particularly for post-operative pain. Key products include EXPAREL for postsurgical pain management, ZILRETTA for osteoarthritis knee pain, and the iovera system for drug-free pain control. Pacira is also developing PCRX-201 for osteoarthritis of the knee.

Pacira BioSciences primarily focuses on the United States as its main market. It has operational presence in Tampa, Florida, and offices in Brisbane, San Diego, California, and Parsippany, New Jersey. Pacira also has operations in the United Kingdom and has an agreement with LG Chem to expand access to EXPAREL in select Asian-Pacific markets.

Pacira BioSciences is known for its commitment to non-opioid pain management. Its focus on non-opioid therapies positions it as a key player in addressing the opioid crisis. Positive clinical data for PCRX-201 enhances its reputation for innovation. Strategic partnerships, such as joining the PROBE Consortium and the agreement with LG Chem, demonstrate market expansion efforts. Activist investor pressure highlights the perceived value of Pacira's assets.

Institutional investors hold a dominant position in Pacira BioSciences, controlling approximately 98.6% to 99.73% of the company's stock. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., Doma Perpetual Capital Management LLC, Dimensional Fund Advisors LP, Renaissance Technologies LLC, D. E. Shaw & Co., Inc., State Street Corp, and Balyasny Asset Management L.P. Individual insider ownership is relatively low, ranging from 1.34% to 4.21%.